Metastatic Colorectal Cancers Completed Phase 1 Trials for Bevacizumab (DB00112)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01183494A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer PatientsTreatment
NCT02069704Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTINĀ®) in First-line Treatment mCRC PatientsTreatment
NCT02641873A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal CancerTreatment
NCT00851136A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)Treatment
NCT00873756A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal CancerTreatment
NCT00920868XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + DasatinibTreatment